Neuron specific enolase as a measure of the efficacy of mexidol in patients with neurologic complications of primary hypothyroidism

Author:
E.B. KUZNETSOVA
Razumovsky Saratov State Medical University, Saratov

Summary:
Objective. To evaluate the activity of neuron specific enolase (NSE) in patients with primary hypothyroidism (PGT) treated with mexidol. Material and methods. Patients with PGT (n=110) were examined before and after treatment. Neuropsychological and neurological status of the patients was studied. To assess the status of the peripheral nervous system, electroneuromyography was performed and serum NSE level was determined. Results and conclusion. The NSE activity depended on gender, age of the patient, duration of endocrinopathy and presence/absence of neurological symptoms. The clear positive dynamics of the majority of the parameters studied was noted during mexidol treatment. The efficacy of antioxidant therapy in these patients was confirmed.

Keywords: neurological complications, primary hypothyroidism, neuron specific enolase, electroneuromyography, mexidol.


Cerebrovascular diseases: perspectives of pathogenetic metabolic correction treatment

Author:
M.M. TANASHYAN, O.V. LAGODA, K.V. ANTONOVA
Research Centre of Neurology, Moscow, Russia

Summary:
Metabolic syndrome is a serious risk factor for acute and chronic cerebrovascular disease, which are a leading cause of disabling conditions. The association of proatherogenic effects of the main components of metabolic syndrome - hyperinsulinemia, arterial hypertension, dyslipidemia and obesity - leads to prominent haemorheological and hemostasis changes, which in turn play a pivotal role in the initiation, course and outcome of cerebrovascular pathology. Metabolic syndrome also influences the efficacy of the main pathogenetic therapy of cerebrovascular diseases — antithrombotic therapy. Thus, primary and secondary prevention of cerebrovascular disease in patients with metabolic syndrome should include haemangiocorrective, antithrombotic, antioxidant and endothelium-protective treatment, as well as therapy of the main components of metabolic syndrome.

Keywords: cerebrovascular disease, metabolic syndrome, haemorheology and haemostasis, antithrombotic therapy, antioxidants.


Specific features of neurological complications developing in patients with type 2 diabetes mellitus and metabolic syndrome: Possibility for correction and prevention

Author:
V.N. SHISHKOVA
Center for Speech Pathology and Neurorehabilitation, Moscow Healthcare Department, Moscow, Russia

Summary:
The prevalence of type 2 diabetes mellitus (DM) and preceding metabolic disturbances has reached epidemic proportions. Oxidative stress plays a significant role in the development of micro- and macrovascular complications in patients with DM. The accumulation of free radicals is responsible for the development of systemic and vascular inflammation, endothelial dysfunction, and hypercoagulable and ischemic states. Since vascular and nervous system damages do not level off even under adequate glycemic control, there is a need for complex pathogenetic treatment strategies. Antioxidant therapy using mexidol is one of the compulsory components of combination therapy for complications of DM.

Keywords: type 2 diabetes mellitus, metabolic syndrome, oxidative stress, mexidol.


Cognitive impairments as a universal clinical syndrome in a therapist’s practice

Author:
V.N. SHISHKOVA
Center for Speech Pathology and Neurorehabilitation, Moscow Healthcare Department, Russia

Summary:
The problem of cognitive dysfunctions in patients with somatic diseases occupies a prominent place now since they are one of the most common manifestations of organic brain lesions. The early detection of potentially cured cognitive impairments is one of the important tasks of a present-day therapist, cardiologist, endocrinologist, and family doctor as the patients with early-stage cognitive impairments constitute the majority of those who have sought medical advice. In the modern world, primary health care physicians’ actions are decisive in predicting the development of dementia since the detection of early non-dementia forms of cognitive impairments and neuroprotective therapy with mexidol in particular are frequently quite sufficient to considerably reduce the degree of the impairments and to improve the prognosis of dementia.

Keywords: cognitive impairments, dementia, mexidol.


Neuroprotection in hypertensive patients: Minimization of poor prognosis

Author:
V.N. SHISHKOVA
Center for Speech Pathology and Neurorehabilitation, Moscow

Summary:
The paper discusses approaches to optimizing pharmacotherapy in patients with hypertension associated with cerebrovascular diseases. Possible indications for neuroprotectors and a pathogenetic rationale for their mechanism of action in patients with prior cerebral stroke are detailed.

Keywords: cerebral stroke, hypertension, neuroprotection.